Teladoc Health Inc (NYSE:TDOC) has earned an average rating of “Buy” from the twenty analysts that are covering the stock, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $85.06.

Several equities research analysts have recently commented on TDOC shares. SunTrust Banks lifted their target price on Teladoc Health to $77.00 and gave the company a “buy” rating in a research note on Thursday, August 9th. Leerink Swann started coverage on Teladoc Health in a research note on Thursday, August 16th. They issued an “outperform” rating and a $90.00 target price for the company. TheStreet raised Teladoc Health from a “d+” rating to a “c” rating in a research note on Wednesday, August 22nd. KeyCorp lifted their target price on Teladoc Health from $74.00 to $90.00 and gave the company an “overweight” rating in a research note on Monday, August 27th. Finally, Canaccord Genuity lifted their target price on Teladoc Health from $70.00 to $86.00 and gave the company a “buy” rating in a research note on Thursday, September 20th.

TDOC stock traded down $2.40 during midday trading on Friday, reaching $53.41. 2,297,900 shares of the company’s stock traded hands, compared to its average volume of 1,353,121. Teladoc Health has a 1-year low of $30.88 and a 1-year high of $89.05. The stock has a market capitalization of $4.19 billion, a price-to-earnings ratio of -32.37 and a beta of 0.92. The company has a debt-to-equity ratio of 0.40, a current ratio of 8.99 and a quick ratio of 8.99.

Teladoc Health (NYSE:TDOC) last released its earnings results on Thursday, November 1st. The health services provider reported ($0.34) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.36) by $0.02. The company had revenue of $111.00 million during the quarter, compared to analysts’ expectations of $109.94 million. Teladoc Health had a negative return on equity of 14.05% and a negative net margin of 31.32%. The business’s revenue for the quarter was up 61.6% on a year-over-year basis. During the same period last year, the firm earned ($0.55) EPS. On average, equities analysts expect that Teladoc Health will post -1.47 earnings per share for the current fiscal year.

In other news, insider Adam C. Vandervoort sold 5,550 shares of the firm’s stock in a transaction on Monday, September 10th. The stock was sold at an average price of $77.67, for a total value of $431,068.50. Following the transaction, the insider now directly owns 2,934 shares in the company, valued at approximately $227,883.78. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Mark Hirschhorn sold 10,000 shares of the firm’s stock in a transaction on Tuesday, December 4th. The stock was sold at an average price of $64.96, for a total value of $649,600.00. Following the completion of the transaction, the chief financial officer now owns 3,285 shares in the company, valued at $213,393.60. The disclosure for this sale can be found here. Insiders sold a total of 255,929 shares of company stock worth $17,683,623 over the last 90 days. 3.95% of the stock is owned by corporate insiders.

Large investors have recently bought and sold shares of the company. Harvest Fund Management Co. Ltd bought a new position in shares of Teladoc Health in the 3rd quarter worth $165,000. Signaturefd LLC bought a new position in Teladoc Health during the third quarter worth about $173,000. Aperio Group LLC bought a new position in Teladoc Health during the second quarter worth about $201,000. California Public Employees Retirement System bought a new position in Teladoc Health during the second quarter worth about $203,000. Finally, Biondo Investment Advisors LLC bought a new position in Teladoc Health during the second quarter worth about $205,000.

About Teladoc Health

Teladoc Health, Inc provides telehealth services worldwide. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.

Recommended Story: Hedge Funds

Analyst Recommendations for Teladoc Health (NYSE:TDOC)

Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.